Berenberg placed a Buy rating on Atai Life Sciences (ATAI) with a $12 price target saying the company has made “exceptional progress” since its initiation with a Positive rating six months ago. Atai has a building pipeline momentum, its funding is secured, Phase 3 entry for its lead programmed is due in the first half 2026, and several more catalysts are expected over the next 12 months, the analyst tells investors in a research note. Berenberg sees the stock’s momentum continuing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
- Atai Life Sciences price target raised to $14 from $11 at Canaccord
- ATAI Life Sciences Closes $149.5 Million Public Offering
- 3 Best Stocks to Buy Now, 10/20/2025, According to Top Analysts
- Atai Life Sciences announces FDA breakthrough designation for BPL-003